Muscle News and Research

RSS

Sirt1 protein enhances skeletal muscle insulin sensitivity in calorie-restricted mice

The number of individuals with type 2 diabetes is reaching epidemic proportions. One of the main risk factors for developing type 2 diabetes is resistance of cells in the body (particularly liver, fat, and skeletal muscle cells) to the effects of the hormone insulin.

11 Oct 2011

Merck’s diabetes combo pill gets FDA nod

The U.S. Food and Drug Administration (FDA) has approved Merck & Co.’s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).

10 Oct 2011

New siRNA treatment reduces damaging inflammation in animals models of several disorders

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions.

10 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

7 Oct 2011

Nutrition tips for long-distance runners

With marathon trainees about to take to the streets of Chicago this Sunday, Loyola University Health System registered dietitian Brooke Schantz offers the top 10 nutrition tips runners can follow to help them cross the finish line.

7 Oct 2011

Scientists discover rare genetic alteration responsible for hypoglycaemia

Cambridge scientists have identified the cause of a rare, life-threatening form of hypoglycaemia. Their findings, which have the potential to lead to pharmaceutical treatments for the disorder, were published today, 07 October, in the journal Science.

7 Oct 2011

Study shows Sox2 expression in many adult stem cells

Investigators at the Massachusetts General Hospital (MGH) Center for Regenerative Medicine and the Harvard Stem Cell Institute (HSCI) have found that Sox2 - one of the transcription factors used in the conversion of adult stem cells into induced pluripotent stem cells (iPSCs) - is expressed in many adult tissues where it had not been previously observed.

7 Oct 2011

Muscle cannot be functionally reactivated if you're too late

When a motor nerve is severely damaged, people rarely recover full muscle strength and function. Neuroscientists from Children's Hospital Boston, combining patient data with observations in a mouse model, now show why. It's not that motor nerve fibers don't regrow – they can – but they don't grow fast enough. By the time they get to the muscle fibers, they can no longer communicate with them.

4 Oct 2011

Merck wins fourth FOSAMAX trial

Merck, known as MSD outside the United States and Canada, today said a federal court jury in New York found in its favor in the Secrest v. Merck case, rejecting the claim of a Florida woman who blamed her dental and jaw-related problems on her FOSAMAX use.

4 Oct 2011

Interactive video games appear to safely enhance physical therapy for ICU patients

Interactive video games, already known to improve motor function in recovering stroke patients, appear to safely enhance physical therapy for patients in intensive care units (ICU), new research from Johns Hopkins suggests.

4 Oct 2011

UCLA neuro-physicists discover optimal brain rhythm for changing synaptic strength

The brain learns through changes in the strength of its synapses -- the connections between neurons -- in response to stimuli. Now, in a discovery that challenges conventional wisdom on the brain mechanisms of learning, UCLA neuro-physicists have found there is an optimal brain "rhythm," or frequency, for changing synaptic strength. And further, like stations on a radio dial, each synapse is tuned to a different optimal frequency for learning.

4 Oct 2011

Interactive video games appear valuable for ICU patients

3 Oct 2011

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

David, a 67-year-old father of three and soon to be first-time grandfather, felt too young to be diagnosed with prostate cancer. "I felt great," he said. "I had no symptoms." David, under the advisement of his oncologist, decided to be treated with PROVENGE (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.

1 Oct 2011

Third Annual Cape Cod Walk 'n' Roll for FSH Muscular Dystrophy on October 1

Tomorrow, October 1, 2011, FSHD patients and their friends, advocates, and families will join in the Third Annual Cape Cod Walk 'n' Roll for FSHD.

1 Oct 2011

Planned clinical trial of Adeona's zinc-based therapy for ALS patients to be featured at ALS Summit

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.

1 Oct 2011

NIH's fourth Symposium on Cardiovascular Regenerative Medicine to be held Oct. 4-5

Advances in tissue engineering and stem cell therapies will be among the research topics discussed during the National Institutes of Health's fourth Symposium on Cardiovascular Regenerative Medicine, which will be held Oct. 4-5.

1 Oct 2011

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

ViroPharma Incorporated today announced the license of worldwide rights from Intellect Neurosciences, Inc. to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease.

1 Oct 2011

European and North American scientists to explore biology of heart failure

A collaborative network of European and North American scientists, including from the University of North Carolina at Chapel Hill School of Medicine, have been awarded a total of $6 million over five years to explore the biology of heart failure and to find new therapies for it.

1 Oct 2011

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.

30 Sep 2011

Muscle News and Research

Sirt1 protein enhances skeletal muscle insulin sensitivity in calorie-restricted mice

Merck’s diabetes combo pill gets FDA nod

New siRNA treatment reduces damaging inflammation in animals models of several disorders

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

Nutrition tips for long-distance runners

Scientists discover rare genetic alteration responsible for hypoglycaemia

Study shows Sox2 expression in many adult stem cells

Muscle cannot be functionally reactivated if you're too late

Merck wins fourth FOSAMAX trial

Interactive video games appear to safely enhance physical therapy for ICU patients

UCLA neuro-physicists discover optimal brain rhythm for changing synaptic strength

Interactive video games appear valuable for ICU patients

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

Third Annual Cape Cod Walk 'n' Roll for FSH Muscular Dystrophy on October 1

Planned clinical trial of Adeona's zinc-based therapy for ALS patients to be featured at ALS Summit

NIH's fourth Symposium on Cardiovascular Regenerative Medicine to be held Oct. 4-5

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

European and North American scientists to explore biology of heart failure

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News